Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2022
Method paper: new version 6.1 comes into force
24 January 2022 - The innovations concern, among other things, the procedure for evidence searches for medical guidelines. New concept ...
Posted by Michael Wonder on 20 Jan 2022
The G-BA classifies three drugs as reserve antibiotics
20 January 2022 - The Federal Joint Committee (G-BA) today exempted three drugs classified as reserve antibiotics from the regular early ...
Posted by Michael Wonder on 20 Jan 2022
Immunotherapy with blinatumomab improves the chances of survival in very rare childhood blood cancer
20 January 2022 - The Federal Joint Committee (G-BA) today classified the additional benefit of the active ingredient blinatumomab as significant ...
Posted by Michael Wonder on 19 Jan 2022
Early benefit assessment for new drugs 2021: G-BA sets a record with 146 completed procedures
10 January 2022 - At the beginning of the year, the Federal Joint Committee (G-BA) took stock of its assessment of ...
Posted by Michael Wonder on 17 Jan 2022
Hyposensitisation with AR101 in peanut allergy: proof of lesser benefit
17 January 2022 - In the patient-relevant outcomes, there are only disadvantages for 4- to 17-year-olds compared to a pure peanut-avoiding ...
Posted by Michael Wonder on 13 Jan 2022
Orphan drugs: privilege of "fictitious" additional benefit not justified
12 January 2022 - Drugs for orphan diseases should also go through a regular benefit assessment procedure when they enter the ...
Posted by Michael Wonder on 04 Jan 2022
Daratumumab in multiple myeloma: reassessment results in hint of considerable added benefit
3 January 2022 - Janssen applied for a new early benefit assessment due to new scientific findings. ...
Posted by Michael Wonder on 14 Dec 2021
Health technology assessment: European Commission welcomes the adoption of new rules to improve access to innovative technologies
13 December 2021 - Today, the Regulation on Health Technology Assessment, a deliverable of the EU Pharmaceutical Strategy, has been adopted. ...
Posted by Michael Wonder on 14 Dec 2021
EU regulation passed: G-BA works on European HTA assessment
14 December 2021 - Today the EU Parliament passed the EU-HTA regulation for a joint health technology assessment, which includes, ...
Posted by Michael Wonder on 09 Dec 2021
Nivolumab for the adjuvant treatment of oesophageal carcinoma: indication of minor added benefit
1 December 2021 - Those affected develop fewer relapses than if they wait and see. ...
Posted by Michael Wonder on 09 Dec 2021
Upadacitinib in atopic dermatitis: additional benefit for adults at high dose
1 December 2021 - Women should expect more serious adverse effects than men. ...
Posted by Michael Wonder on 11 Nov 2021
European Council green lights new rules on health technology assessment, improving access to medicines and simplifying procedures
9 November 2021 - The Council today gave its final go-ahead for the adoption of a regulation on health technology assessment. ...
Posted by Michael Wonder on 08 Nov 2021
Drugs against rare diseases: Libmeldy gene therapy shows additional benefits - Zolgensma cell therapy, on the other hand, does not
4 November 2021 - The Federal Joint Committee (G-BA) today assessed the additional benefit of two active ingredients against very rare, ...
Posted by Michael Wonder on 05 Oct 2021
Nivolumab and ipilimumab: added benefit in pleural mesothelioma with non-epithelioid tumour histology
1 October 2021 - For the first time, a pure antibody combination has been approved as a first-line therapy for ...
Posted by Michael Wonder on 05 Oct 2021
Adjuvant treatment for NSCLC: osimertinib mesylate may benefit certain people
1 October 2021 - Hint of considerable additional benefit if, after complete tumour resection, adjuvant platinum-based chemotherapy has already been ...